Where does Ultragenyx Pharmaceutical's cash flow data come from?

Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$608.92M-5.9%	-$574.92M+0.8%	-$579.57M-8.8%	-$532.67M+3.0%	-$549.32M+3.5%
Depreciation and amortization	$34M-2.9%	$35M-2.1%	$35.75M-0.4%	$35.9M-0.7%	$36.16M+0.4%
Change in accounts receivable	$22M-29.0%	$31M+70.3%	$18.21M—	——	——
Change in inventories	——	——	——	——	$9.88M-10.2%
Other working capital changes	——	——	——	——	——
Change in deferred revenue	——	——	——	——	——
Net cash from operating activities	-$497M-6.7%	-$466M-4.6%	-$445.49M-5.8%	-$421.06M-8.2%	-$389.27M+6.0%
Capital expenditures	$6M0.0%	$6M+14.8%	$5.23M-6.1%	$5.56M+16.2%	$4.79M-31.6%
Purchases of investments	$317M+70.4%	$186M+281%	$48.77M-87.8%	$399.2M+3.1%	$387.07M-5.4%
Proceeds from maturities/sales of investments	——	——	——	——	$137.3M+4,262%
Purchases of intangible assets	——	——	——	——	$18M+38.5%
Other investing activities	——	——	——	——	——
Net cash from investing activities	——	——	——	——	——
Effect of exchange rate changes on cash	——	——	$2.71M—	——	——
Net increase (decrease) in cash	$50M-80.2%	$252M—	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$3M-25.0%	$4M-40.0%	$6.67M-26.6%	$9.08M-19.3%	$11.24M-13.5%
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost	$143M-6.5%	$153M-1.8%	$155.85M-2.7%	$160.15M-0.6%	$161.07M+1.9%
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities	$15M-37.5%	$24M-28.1%	$33.38M+3,709%	-$925K-103%	$34.54M-26.5%
Prepaid expenses and other current assets	——	——	——	$4.45M-60.6%	$11.28M+192%
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	$68.66M+11.4%	$61.66M+6.9%	$57.67M-2.6%	$59.23M-3.1%	$61.15M-2.9%
Non Cash Royalty Revenue	$113M+0.9%	$112M+3.7%	$108.01M+1.7%	$106.16M+4.1%	$101.94M+0.9%
Other Noncash Income (Expense)	——	——	——	——	——
Payment for (Proceeds from) Other Investing Activity	——	——	——	——	——
Payments to Acquire Intangible Assets	——	——	——	——	$18M+38.5%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$395M-11.0%	$444M-7.7%	$481.21M+9.6%	$439.19M+5.0%	$418.21M+2.0%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	$2.71M—	——	——
Free cash flow	-$503M-6.6%	-$472M-4.7%	-$450.71M-5.6%	-$426.62M-8.3%	-$394.06M+6.4%
Free cash flow	-$503M-6.6%	-$472M-4.7%	-$450.71M-5.6%	-$426.62M-8.3%	-$394.06M+6.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Ultragenyx Pharmaceutical's cash flow data come from?: Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.